FOI Request
- Disclosure ID
- FOI/03489
- Request Date
- January 6, 2020
- Subject
- VTE Protocols & Volumes
- Description
1). Does a specific venous thromboembolism protocol exist for your Trust
If so:
– What date was this protocol put into place
– When is it due for review
2). Is there a preferred Direct Oral Anticoagulant (DOAC) or are all utilised within the trust for VTE.
3). How many patients have been treated for VTE with a DOAC in the last 12 months.
4). What volume of each DOAC was used to Treat in this same time period.
- Response
1). A specific venous thromboembolism protocol does exist for our Trust. Corp/Guid/076
– This protocol was put into place 13/05/2019
– This protocol is due for renewal 13/05/2022
2). DOACs are utilised to meet the clinical needs of the patient.
Please see figures below for preferred DOAC.
3). Our Trust does not record drug use with respect to clinical indication. To retrieve this information would require a manual trawl of patient case notes which would exceed 18 hours. This information is therefore exempt on the grounds of cost (Section 12(1)).
Below are the total quantities of stock dispensed (in tablets) from our pharmacy to both wards and patients for the last 12 months, we do not record the prescribed amount.
Drug Number of Tablets Apixaban 190,707 Dabigatran 6,560 Edoxaban 27,567 Rivaroxaban 22,267 4). Volume of DOACs used will depend on the clinical needs of the patients .
To retrieve this information would require a manual trawl of patient case notes which would exceed 18 hours. This information is therefore exempt on the grounds of cost (Section 12(1)).